S. Gallinger

Abstract B066: Convergent cell-state programs characterize BRCA2 -reversion-independent resistance in pancreatic cancer

Most patients with pancreatic ductal adenocarcinoma (PDAC) present with advanced-stage disease, for which systemic therapy is the mainstay, highlighting the need to identify therapeutically vulnerable molecular tumor subgroups. Homologous recombination deficiency (HRD), arising from germline or somatic alterations in...

Abstract B036: Systematic Germline and Tumor Genomic Analysis for Gene Discovery in Familial Pancreatic Cancer

Despite the identification of several pancreatic ductal adenocarcinoma (PDAC) predisposition genes, more than 75% of familial pancreatic cancer (FPC) families remain genetically unexplained. To address this, we developed a systematic discovery pipeline focused on families with multiple affected individuals, leveragin...

Multimodal Machine Learning for Predicting Outcomes in the PASS-01 Trial of Systemic Therapy for Metastatic Pancreatic Cancer

Multi-modal digital twin model outperforms conventional biomarker stratification in pancreatic cancer

Better patient selection for treatment is critical to improving both cancer care and therapeutic development in oncology. The ability to predict individual patient responses to cancer treatment ahead of time would transform cancer care with substantial impact on outcomes, quality of life and cost. We generated molecula...